## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

For: THERAPY OF NON-MALIGNANT )
DISEASES OR DISORDERS WITH )
ANTI-ErbB2 ANTIBODIES )

Customer No. 25213

## FILED VIA EFS - MARCH 28, 2007

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign Insquare, if any, pursuant to 37 C.F.R. § 1971-79.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If Form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with M.P.E. P. 6699.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

$\boxtimes$	This st	This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):						
		(1)	is being filed within 3 months of the application filing date and is other than a continued assecution application under § 1.53(d)  — OR —					
		(2)	OR  It is being filed within 3 months of entry of a national stage OR					
		(3)	It is being filed before the mail date of the first Office Action on the merits  OR -					
		(4)	It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under $\S$ 1.114.					
	37 C.F.R. §1.97(c). If this statement is being filled after the latest of: (1) three months beyond the filling date of a national application; (2) three months beyond the date of entry of the national stage as set forth m §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:							
		a certif	ication as specified in §1.97(e) is provided below; or					
		a fee of \$180.00 as set forth in $\S1.17(p)$ is authorized below, enclosed, or included with the payment of other papers filed together with this statement.						
	37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:							
	A.	a certification as specified in §1.97(e) is completed below; and						
	B.	a petition under 37 C.F.R. $\S1.97(d)$ requesting consideration of this statement is submitted herewith; and						
	C.	a fee of \$180.00 as set forth in $\S1.17(i)(1)$ is authorized below, enclosed, or included with the payment of other papers filed together with this statement.						
	Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$-0- and charge any additional fees or ordist my overpayment associated with this communication to Deposit Account No. 90-1641 (Ducket No. 39766-0205).							
			n an 1 5 1					

Respectfully submitted,

Ginger R. Dreger, Esq. Reg. No. 33,055

Dated: March 28, 2007

HELLER EHRMAN LLP Customer No. 35489 275 Mrddleffeld Road Menlo Park, CA 94025-3506 Telephone: (650) 324-7000 Facsimile: (650) 324-0638

SEDIAL NO

	TATEMENT	SURE	39766-0205	107	719,310			
	PTO-1449		APPLICANT: BRUNETTA, et al.					
	110-147		FILING DATE: 11/21/2003 GROUP: 1644					
		U.	S. PATENT DOCUMENTS					
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING	G DATE	
2.110.00								
						-		
						-		
				-		-		
				-				
				-		-		
			-	-		-		
				1		-		
				<del> </del>		-		
				1				
				1				
		FOR	EIGN PATENT DOCUMENTS					
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
INTIALS			-			YES	NO	
	L		I		L			
	Haase, et al., "A	Role for Mits	Including Author, Title, Date, P ogen-Activated Protein Kinase Ac nical Investigation, 108(4); 527-5:	tivation by I	ntegrins in the l	Pathogen	esis of	
EXAMINER			DATE CONSIDERED		· · · · · · · · · · · · · · · · · · ·			
EY AMINED - Name of			in his and a service of					

ATTY DOCKET NO :